SCHEMBL20164651

SCHEMBL20164651

CCNc1nc(NCC(C)(C)O)c2nc(NCC)nc(NCC)c2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 1/20 0.41
LMNA P02545 3/20 0.37
FLT3 P36888 1/20 0.36
PRKCD Q05655 1/20 0.36
CAMK2B Q13554 1/20 0.36
CAMK2G Q13555 1/20 0.36
CAMK2D Q13557 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CCNE1 P24864 3/20 0.35
CDK2 P24941 3/20 0.35
CDK5 Q00535 3/20 0.35
CDK7 P50613 2/20 0.35
CCNH P51946 2/20 0.35
CDK5R1 Q15078 2/20 0.35
GAA P10253 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
CCNT1 O60563 1/20 0.35
CDK9 P50750 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL20164735 0.98 SLC29A1 (0.41) SLC29A1LMNAFLT3PRKCDCAMK2B
SCHEMBL20164502 0.91 SLC29A1 (0.48) SLC29A1LMNAFLT3PRKCDCAMK2B
Hydrochloric Acid SCHEMBL20164610 0.89 SLC29A1 (0.47) SLC29A1LMNAFLT3PRKCDCAMK2B
SCHEMBL20164661 0.87 SLC29A1 (0.48) SLC29A1LMNAFLT3PRKCDCAMK2B
SCHEMBL20164311 0.87 SLC29A1 (0.35) SLC29A1LMNAFLT3PRKCDCAMK2B
Hydrochloric Acid SCHEMBL20164559 0.86 SLC29A1 (0.47) SLC29A1LMNAFLT3PRKCDCAMK2B
Hydrochloric Acid SCHEMBL20164324 0.85 SLC29A1 (0.35) SLC29A1LMNAFLT3PRKCDCAMK2B
SCHEMBL18806440 0.83 LMNA (0.50) SLC29A1LMNAFLT3PRKCDCAMK2B
SCHEMBL20164707 0.79 LRRK2 (0.36) SLC29A1CCNE1CDK2CDK5CDK7
Hydrochloric Acid SCHEMBL20164642 0.78 LRRK2 (0.36) SLC29A1CCNE1CDK2CDK5CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250057848-A1 GAL475 COMPOSITIONS AND METHODS OF USE THEREOF NEURIM PHARMACEUTICALS (1991) LTD. (IL) 2025-02-20 US disclosed
EP-3316890-B1 NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME NEURAD LTD (IL) 2023-09-06 EP disclosed
EP-3316890-B1 NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME NEURAD LTD (IL) 2023-09-06 EP disclosed
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same NEURAD LTD. (IL) 2019-05-21 US disclosed
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same NEURAD LTD. (IL) 2019-05-21 US disclosed
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same NEURAD LTD. (IL) 2018-05-24 US disclosed
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same NEURAD LTD. (IL) 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same MTNR1B, CHRM3, PER2 SLC29A1 4472/4885LMNA 1394/4885FLT3 4814/4885
US-20250057848-A1 GAL475 COMPOSITIONS AND METHODS OF USE THEREOF GPR119, GPR35, GPR55 SLC29A1 2077/4885LMNA 2585/4885FLT3 4608/4885
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same MTNR1B, PDE3A, CHRM3 SLC29A1 4518/4885LMNA 1200/4885FLT3 4789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.